

THE POSSIBILITIES ARE  
LIMITLESS

## IASLC 2019 World Conference on Lung Cancer

INDUSTRY SYMPOSIUM

# TODAY'S GENOMIC SOLUTIONS. TOMORROW'S CANCER BREAKTHROUGHS.

### Benefiting Lung Cancer Patients With Comprehensive Genomic Profiling

Consolidation of single gene tests into a hybrid-capture next-generation sequencing (NGS) assessment – could this be the path forward? This workshop will focus on the benefits of Comprehensive Genomic Profiling (CGP) in lung cancer, where available sample material is usually limited. CGP provides measurement of key biomarkers, including TMB and MSI, and fusion identification.

**Chair:** *Sandip Patel, MD, Associate Professor, UC San Diego Health, USA*

- **Transforming Oncology with Comprehensive Genomic Profiling**

*David Eberhard, MD, PhD, Senior Medical Director, Oncology, Illumina, USA*

- **Diagnostic and Clinical Utility of Common to Rare Fusions in Lung Cancer**

*Ahmet Zehir, PhD, Director, Clinical Bioinformatics, Memorial Sloan Kettering Cancer Center (MSKCC), New York, USA*

- **Q&A**

**WHEN:** Monday 9 September | 7AM – 8AM

**WHERE:** Vienna (2016), Hall 8.0

*Tea, coffee and light refreshments will be available prior to the workshop, courtesy of Illumina.*

**VISIT ILLUMINA BOOTH 607**

*This program was approved by the IASLC 2019 World Conference on Lung Cancer Program Committee as an independent activity held in conjunction with the IASLC 2019 World Conference on Lung Cancer. This program is not sponsored or endorsed by IASLC and is not part of the official IASLC accredited program.*

© 2019 Illumina, Inc. All rights reserved. [www.illumina.com](http://www.illumina.com).

illumina®

QB# 8028